Novavax Inc
Change company Symbol lookup
Select an option...
NVAX Novavax Inc
UHT Universal Health Realty Income Trust
BBVA Banco Bilbao Vizcaya Argentaria SA
RILY B Riley Financial Inc
WTS Watts Water Technologies Inc
MMM 3M Co
ADTH AdTheorent Holding Company Inc
GAZ iPath? Series B Bloomberg Natural Gas Subindex Total ReturnSM ETN
SNAP Snap Inc
FNB FNB Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Closing Price
$11.23
Day's Change
-0.78 (-6.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.28
Day's Low
11.18
Volume
(Average)
Volume:
6,466,637

10-day average volume:
7,009,341
6,466,637

Display:

Providers:

UpdateCancel
6 providers
January 25, 2023
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax, Inc. (Nasdaq: NVAX), abiotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has granted a non-qualified stock option and restricted stock units to...(PR Newswire)

January 18, 2023
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

Novavax, Inc. (Nasdaq: NVAX), abiotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner SK bioscience has received expanded manufacturing and marketing...(PR Newswire)

January 09, 2023
Novavax Names John C. Jacobs as New President & Chief Executive Officer

-- Current President & CEO Stanley C. Erck will retire effective January 23 with plans to support the leadership transition in an advisory capacity -- Novavax is well-positioned to execute on its strategy, with global authorizations for its...(PR Newswire)

December 30, 2022
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CIC)...(PR Newswire)

December 28, 2022
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previously...(PR Newswire)

December 15, 2022
Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its...(PR Newswire)

Novavax Announces Pricing of $65 Million Public Offering of Common Stock

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an underwrittenpublicoffering tosell 6,500,000 shares of...(PR Newswire)

December 14, 2022
Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed offering of $125 million aggregate principal amount of convertible...(PR Newswire)

Novavax Announces Proposed $125 Million Public Offering of Common Stock

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwrittenpublic offeringtosell up to$125 million of...(PR Newswire)

December 07, 2022
Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has approved a supplement to a New Drug Submission (sNDS)...(PR Newswire)

December 02, 2022
Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap...(PR Newswire)

November 29, 2022
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use...(PR Newswire)

November 14, 2022
Novavax to Participate in Jefferies London Healthcare Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the Jefferies London Healthcare Conference...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.